Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL-ND NPM1: revumenib plus intensive chemotherapy in newly diagnosed NPM1-mutant AML
MOH_2026-01-26_015618Phase 3Not yet recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Revufori + intensive chemotherapy with Placebo + intensive chemotherapy (2 arms). Primary endpoints: Event-free survival and Bone marrow measurable residual disease rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2026-01-26_015618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-26_015618.